10.1186/s12933-016-0468-4 9
These medications support fertility only while they improve metabolic signaling without suppressing ovulation
Through August 31, 2026, pay $149/month for the two lowest doses of daily Wegovy pills through a Novo Nordisk offer, subsequent doses are up to $299/month, restrictions and exclusions apply.** Or through June 30, 2026, get your first two months of weekly Wegovy injectables for $199/month through an introductory Novo Nordisk offer, subsequent doses up to $349/month, restrictions and exclusions apply
R This is one mechanism linking slow acetylator status to increased bladder and colorectal cancer risk
Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease